Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Background: Teclistamab (Tec), a first-in-class BCMA bispecific T-cell antibody, received regulatory approval for the treatment of RRMM based on the MajesTEC-1 study [Moreau et al, NEJM, 2022] which demonstrated an overall response rate (ORR) of 63% and median progression free survival (PFS) of 11.3...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2024-11, Vol.144 (Supplement 1), p.934-934
Main Authors: Pasvolsky, Oren, Dima, Danai, Feng, Lei, Dong, Wenli, Richards, Tiffany, Davis, James A, Afrough, Aimaz, Vazquez-Martinez, Mariola A, Sannareddy, Aishwarya, Goel, Utkarsh, Banerjee, Rahul, Khouri, Jack, Curet, Frances N. Cervoni, Gaballa, Mahmoud R., Lieberman-Cribbin, Alex, Rana, Masooma S, Julian, Kelley, Ferreri, Christopher J, Shune, Leyla O., DeJarnette, Shaun, Ouchveridze, Evguenia, Susanibar-Adaniya, Sandra, Portuguese, Andrew J., Hosoya, Hitomi, Mikkilineni, Lekha, Kaur, Gurbakhash, Rossi, Adriana, Herr, Megan M, Schrum, Daniel, Lin, Chenyu, Raza, Shahzad, Lin, Yi, Atrash, Shebli, McGuirk, Joseph P., Sborov, Douglas W, Voorhees, Peter M., Anwer, Faiz, Alsina, Melissa, Freeman, Ciara Louise, Garfall, Alfred L., Sidana, Surbhi, Cowan, Andrew J., Anderson, Larry D, Hansen, Doris K., Richard, Shambavi, Patel, Krina K., Lee, Hans C., Grajales-Cruz, Ariel
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Teclistamab (Tec), a first-in-class BCMA bispecific T-cell antibody, received regulatory approval for the treatment of RRMM based on the MajesTEC-1 study [Moreau et al, NEJM, 2022] which demonstrated an overall response rate (ORR) of 63% and median progression free survival (PFS) of 11.3 months. However, less than 15% (N=24) of patients (pts) enrolled in MajestTEC-1 were ≥75 years, an age cohort that is often underrepresented in clinical trials and comprises approximately one third of MM pts at diagnosis [SEER 22 2017-2021]. In this multicenter retrospective study, we report the real-world safety and efficacy of a large cohort of elderly (≥75 years) RRMM pts treated with Tec. Methods: Pts with RRMM who received standard-of-care Tec across 13 U.S. academic institutions were included in the study. The follow-up data cutoff was 30 April 2024. Pts were divided by age into two groups: age
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2024-205989